CRISPR/Cas9 Market Size, Share & Trends Analysis By Product (CRISPR Cas9 Reagents, CRISPR Cas9 Libraries, CRISPR Delivery Systems, CRISPR Software Tools), By Application (Gene Therapy, Drug Discovery, Agricultural Genomics, Diagnostics, Functional Genomics), By End-Use (Biopharmaceutical Companies, Research Institutes, CROs, Agricultural Biotech), By Region, And Segment Forecasts, Market Size, Market Share, and Forecast Analysis, 2026 – 2036

Market Overview

According to Novatrends Market Intelligence, the Global CRISPR/Cas9 Market was valued at USD 3.84 billion in 2025 and is anticipated to propel at a growth rate of 18.4% from 2026-2036.

The CRISPR/Cas9 market encompasses CRISPR Cas9 reagents (Cas9 protein, CRISPR guide RNA, CRISPR ribonucleoprotein RNP), CRISPR Cas9 libraries, CRISPR delivery systems (lipid nanoparticle LNP delivery, AAV delivery, electroporation), and CRISPR software tools for gene therapy, drug discovery, agricultural genomics, diagnostics, and functional genomics applications by biopharmaceutical companies, research institutes, CROs, and agricultural biotech end-users. CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9) is a revolutionary genome editing technology — a bacterial adaptive immune system component adapted by Drs. Jennifer Doudna and Emmanuelle Charpentier (2020 Nobel Prize in Chemistry) into a programmable, precise DNA editing tool where a single guide RNA (sgRNA, CRISPR guide RNA) directs Cas9 protein endonuclease to a specific genomic target sequence for site-specific double-strand DNA break and subsequent gene knockout, correction, or insertion via cellular DNA repair mechanisms. CRISPR technology market spans CRISPR Cas9 (the original Class 2 Type II CRISPR system), Cas12a/Cpf1, Cas13 (RNA-targeting), base editing CRISPR (cytosine and adenine base editors that convert single DNA bases without DSB), and prime editing CRISPR (search-and-replace genome editing with no DSB) — Beam Therapeutics CRISPR base editing and prime editing CRISPR are the leading next-generation CRISPR technology platforms beyond standard Cas9. CRISPR therapeutics market (in vivo and ex vivo gene therapy using CRISPR Cas9 genome editing) has achieved the first approved CRISPR gene therapy — Casgevy (Vertex/CRISPR Therapeutics), FDA and EMA approved for sickle cell disease and beta-thalassemia in 2023-2024 — marking a pivotal milestone. Intellia Therapeutics CRISPR (in vivo LNP-delivered CRISPR gene therapy for transthyretin amyloidosis NTLA-2001 and other targets) and Editas Medicine CRISPR (CRISPR Cas9 ex vivo cell therapy EDIT-301 for hemoglobinopathies) are leading CRISPR therapeutics clinical stage programs. Beam Therapeutics CRISPR base editing is advancing in vivo and ex vivo base editing programs for sickle cell disease, leukemia, and metabolic disorders. CRISPR delivery system (LNP-CRISPR, AAV-CRISPR, electroporation CRISPR RNP delivery for ex vivo cell editing) is a critical technology component enabling in vivo CRISPR gene therapy delivery efficiency and safety. CRISPR Cas9 reagents (Cas9 protein recombinant, synthetic CRISPR guide RNA, gRNA design and synthesis, CRISPR RNP complexes) are supplied by Integrated DNA Technologies (IDT), Thermo Fisher Scientific, Horizon Discovery (PerkinElmer), and other genomics reagent suppliers for research and translational CRISPR applications. CRISPR Cas9 libraries (genome-wide sgRNA libraries for CRISPR functional genomic screens) enable high-throughput identification of therapeutic targets and drug resistance mechanisms in drug discovery. CRISPR diagnostics (SHERLOCK, DETECTR platforms using Cas12/Cas13 for nucleic acid detection) are a growing CRISPR application pioneered by Sherlock Biosciences and Mammoth Biosciences for rapid diagnostic test development. Benchling CRISPR software provides CRISPR guide RNA design, off-target analysis, and experiment management software tools for CRISPR research workflows. CRISPR agricultural genomics is using Cas9 and Cas12 to develop disease-resistant, drought-tolerant, and yield-improved crop varieties. CRISPR Cas9 market size is driven by CRISPR therapeutics approvals, research reagent demand growth, and agricultural biotech adoption globally.

Market Dynamics

The market is driven by CRISPR gene therapy approval and clinical pipeline expansion — Casgevy approval for sickle cell disease and beta-thalassemia has validated the CRISPR therapeutics market and catalyzed investment in next-generation CRISPR gene therapy programs from Intellia, Editas, Beam, and multiple biopharmaceutical companies, research institute and biopharmaceutical CRISPR Cas9 reagents demand growth with CRISPR becoming a standard genomics research tool replacing zinc finger nuclease and TALEN methods for virtually all gene editing research applications, and CRISPR delivery system innovation — in vivo LNP delivery of CRISPR Cas9 enabling systemic organ targeting beyond the liver, advancing Intellia Therapeutics CRISPR programs for non-liver targets. CRISPR technology market is expanding with base editing CRISPR and prime editing CRISPR advancing next-generation precision editing beyond standard Cas9 indel-based knockout. Editas Medicine CRISPR and CRISPR Therapeutics (Vertex partnership) are driving clinical-stage gene therapy programs. CRISPR diagnostics is growing with nucleic acid CRISPR-based rapid test platform development. CRISPR Cas9 market growth is supported by NIH and government research funding and pharma R&D investment. CRISPR agricultural genomics is gaining regulatory clarity with USDA biotech regulation updates for CRISPR-edited crops in the U.S. Benchling CRISPR software is growing in biopharma workflow adoption. CRISPR Cas9 market trends show growing CRISPR therapeutics, base editing, and CRISPR delivery system innovation globally. In January 2024, Intellia Therapeutics expanded CRISPR therapeutics and CRISPR delivery system with NTLA-2001 in vivo LNP CRISPR program Phase 2 data, while Beam Therapeutics advanced base editing CRISPR with BEAM-101 sickle cell base editing clinical trial programs. CRISPR Cas9 market trends show growing therapeutics, diagnostics, and agricultural CRISPR market demand globally through 2036.

Segment Analysis

By Product: CRISPR Cas9 Reagents holds the largest share of the CRISPR/Cas9 market, supported by strong adoption and well-established supply chains across key end-use industries. CRISPR Cas9 Libraries is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

By Application: Gene Therapy holds the largest share of the CRISPR/Cas9 market, supported by strong adoption and well-established supply chains across key end-use industries. Drug Discovery is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

By End-Use: Biopharmaceutical Companies holds the largest share of the CRISPR/Cas9 market, supported by strong adoption and well-established supply chains across key end-use industries. Research Institutes is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

Recent Developments in CRISPR/Cas9 Market

• In January 2024, Intellia Therapeutics Inc. (USA) expanded Intellia Therapeutics CRISPR and CRISPR delivery system with NTLA-2001 in vivo LNP-CRISPR Phase 2 transthyretin amyloidosis gene therapy program, advancing CRISPR for gene therapy, CRISPR Cas9 market growth, and CRISPR therapeutics market for in vivo liver target CRISPR gene therapy programs globally.
• In April 2024, Beam Therapeutics Inc. (USA) advanced Beam Therapeutics CRISPR and base editing CRISPR with BEAM-101 and BEAM-201 base editing gene therapy clinical programs for sickle cell disease and T-cell acute lymphoblastic leukemia, expanding prime editing CRISPR, CRISPR Cas9 reagents, and CRISPR gene editing market growth for ex vivo and in vivo therapeutics programs globally.
• In July 2024, Editas Medicine Inc. (USA) expanded Editas Medicine CRISPR and CRISPR Cas9 market with EDIT-301 Cas12a-based ex vivo cell therapy for sickle cell disease and beta-thalassemia clinical programs, advancing CRISPR for gene therapy, CRISPR delivery system, and CRISPR technology market growth for hemoglobinopathy gene therapy programs globally.
• In September 2024, Integrated DNA Technologies (IDT, Danaher) advanced CRISPR Cas9 reagents and CRISPR guide RNA with IDT Alt-R CRISPR Cas9 system and crRNA/tracrRNA innovations, expanding Cas9 protein market, CRISPR Cas9 libraries, and CRISPR technology market growth for research institute and biopharmaceutical CRISPR functional genomics and drug discovery programs globally.
• In December 2024, Vertex Pharmaceuticals / CRISPR Therapeutics AG (USA/Switzerland) expanded CRISPR therapeutics market with Casgevy commercial launch and post-approval expansion programs for sickle cell disease and beta-thalassemia, advancing CRISPR for gene therapy, CRISPR delivery system, and CRISPR Cas9 market growth for commercialized CRISPR gene therapy global market programs globally.
• In March 2025, Mammoth Biosciences Inc. (USA) advanced CRISPR diagnostics and CRISPR technology market with Mammoth Biosciences Cas12 and Cas14 SHERLOCK-based CRISPR diagnostic platform innovations, expanding CRISPR guide RNA, CRISPR Cas9 reagents, and CRISPR Cas9 market growth for point-of-care CRISPR diagnostics and functional genomics research programs globally.

Top CRISPR/Cas9 Market - Key Market Players

• Intellia Therapeutics Inc.
• Beam Therapeutics Inc.
• Editas Medicine Inc.
• Integrated DNA Technologies (IDT)
• CRISPR Therapeutics AG
• Mammoth Biosciences Inc.
• Thermo Fisher Scientific (Life Technologies)
• Horizon Discovery (PerkinElmer)
• Merck KGaA (MilliporeSigma CRISPR)
• Caribou Biosciences (USA)
• Benchling Inc. (USA)
• Sherlock Biosciences (USA)
• Prime Medicine Inc. (USA)
• Graphite Bio Inc. (USA)
• Inscripta Inc. (USA)

Global CRISPR/Cas9 Market Report- Scope (Customizable)

Detailed Market Segmentation

• By Product (Revenue in USD Million)
  • CRISPR Cas9 Reagents
  • CRISPR Cas9 Libraries
  • CRISPR Delivery Systems
  • CRISPR Software Tools
• By Application (Revenue in USD Million)
  • Gene Therapy
  • Drug Discovery
  • Agricultural Genomics
  • Diagnostics
  • Functional Genomics
• By End-Use (Revenue in USD Million)
  • Biopharmaceutical Companies
  • Research Institutes
  • CROs
  • Agricultural Biotech
• By Region (Revenue in USD Million)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Russia
    • Italy
    • Spain
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Central & South America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt
    • South Africa